Effects of verdelezumab combined with mesalazine on intestinal mucosal barrier function and IL-23/IL-17 axis in patients with ulcerative colitis
Objective To analyze the effects of verdelezumab combined with mesalazine on intesti-nal mucosal barrier function and interleukin-23(IL-23)/interleukin-17(IL-17)axis in patients with ulcerative colitis(UC).Methods A total of 106 patients with ulcerative colitis admitted to Lujiang County People's Hos-pital from January 2020 to December 2022 were selected as the study subjects and divided into a combination group(n=53)and a control group(n=53)using a random number table method.The control group received oral mesalazine treatment,and the combination group received verderizumab treatment in addition to the control group's treatment.Both groups underwent a 14-week treatment period,and their therapeutic effects were com-pared.Clinical disease activity index(CAI)and inflammatory bowel disease questionnaire(IBDQ)scores were assessed before and after treatment.Intestinal mucosal barrier function(D-lactic acid,endotoxin),T helper cell 17(Th17),T regulatory cell(Treg),IL-23 and IL-17 levels were compared between the two groups before treatment,at 6 weeks and at 14 weeks of treatment.The incidence of adverse drug reactions was also compared between the two groups.Results The effective rate of the combination group was superior to that of the control group,the difference was statistically significant(x2=4.711,P<0.05).The CAI and IBDQ scores of the combi-nation group were better than those of the control group after treatment,and the differences were statistically sig-nificant(t=9.625,5.291;P<0.05).The levels of D-lactic acid,endotoxin,Th17,IL-23,and IL-17 in the pe-ripheral blood of the combination group were lower than those of the control group after 6 and 14 weeks of treat-ment,and the differences were statistically significant(t=5.620,7.190;5.295,7.737;2.820,3.921;5.635,9.463;6.937,9.516;P<0.05).Treg levels in the peripheral blood of the combination group were higher than those of the control group after 6 and 14 weeks of treatment,and the differences were statistically significant(t=2.790,3.008;P<0.05).There was no significant difference in the incidence of adverse drug reactions between the combination group and the control group(x2=0.135,P>0.05).Conclusion Verdelezumab combined with mesalazine can effectively improve the quality of life and protect the intestinal mucosal barrier function in pa-tients with UC.The mechanism may be related to the inhibition of the IL-23/IL-17 axis.
NETL
NSTL
万方数据
